Results 101 to 110 of about 2,230 (120)

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program. [PDF]

Respir Res
Lucca F, Pianazzola A, Meneghelli I, Catanzaro G, Sabbioni G, Tridello G, Hristodor AM, De Luca E, Menichetti G, Breveglieri G, Altieri MT, Bordicchia M, Fabrizzi B, Ferretti E, Lippi G, Ros M, Borgatti M, Cipolli M, Bezzerri V.   +18 more
europepmc   +1 more source

Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? [PDF]

Am J Respir Crit Care Med
Wilson G, Hughes D.
europepmc   +1 more source

Home sputum collection for <i>Aspergillus fumigatus</i> detection in adults with cystic fibrosis. [PDF]

ERJ Open Res
Hong G, Walsh J, Koshy A, Hsu JY, O'Dea AL, Vesely EM, Memon W, Dezube RH, Goss CH, Goss LB, Greene A, Gross JE, Wilson A, Nichols DP, Zhang SX, Cramer RA.   +15 more
europepmc   +1 more source

Elexacaftor-tezacaftor-ivacaftor and cystic fibrosis liver disease: A turning point that calls for cautious optimism. [PDF]

JHEP Rep
Rautou PE, Hillaire S, Gambazza S, Colombo C.   +3 more
europepmc   +1 more source

Development and Validation of a New LC-MS/MS Method for Simultaneous Quantification of Ivacaftor, Tezacaftor and Elexacaftor Plasma Levels in Pediatric Cystic Fibrosis Patients. [PDF]

Pharmaceuticals (Basel)
Mancini A, Simeoli R, Cristiani L, Cairoli S, Ciciriello F, Boni A, Alghisi F, Rossi C, Antonetti G, Vici CD, Fiocchi AG, Cutrera R, Goffredo BM.   +12 more
europepmc   +1 more source

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis. [PDF]

J Clin Invest
Baumlin N, Gunewardena S, Randell SH, Horrigan FT, Salathe M.   +4 more
europepmc   +1 more source

Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study. [PDF]

Life (Basel)
Tosto M, Parisi GF, Presti S, Papale M, Pecora G, Mulè E, Ornato V, Aloisio D, Manti S, Leonardi S.   +9 more
europepmc   +1 more source

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. [PDF]

Clin Transl Sci
Perrotta N, Fiorito LA, Gentile R, Vescovo R, Piciocchi A, Troiani P, Poscia R, Cimino G.   +7 more
europepmc   +1 more source

Hitting the Sweet Spot: The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis. [PDF]

Am J Respir Crit Care Med
Douglas TA, McMahon SK, Wainwright CE.
europepmc   +1 more source